Tilt Investment Management Holdings PBC Lowers Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Tilt Investment Management Holdings PBC lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 26.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,543 shares of the medical research company’s stock after selling 568 shares during the period. Thermo Fisher Scientific accounts for 0.9% of Tilt Investment Management Holdings PBC’s investment portfolio, making the stock its 25th largest holding. Tilt Investment Management Holdings PBC’s holdings in Thermo Fisher Scientific were worth $820,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. WCM Investment Management LLC increased its position in Thermo Fisher Scientific by 0.3% during the fourth quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock valued at $527,524,000 after acquiring an additional 2,928 shares during the last quarter. Phoenix Holdings Ltd. increased its position in Thermo Fisher Scientific by 21.4% during the third quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock valued at $4,750,000 after acquiring an additional 1,654 shares during the last quarter. DMC Group LLC increased its position in Thermo Fisher Scientific by 16.5% during the third quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock valued at $300,000 after acquiring an additional 84 shares during the last quarter. S. R. Schill & Associates increased its position in Thermo Fisher Scientific by 106.3% during the fourth quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock valued at $816,000 after acquiring an additional 792 shares during the last quarter. Finally, Check Capital Management Inc. CA bought a new position in Thermo Fisher Scientific during the third quarter valued at $219,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares in the company, valued at approximately $27,311,992.65. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the sale, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 5,547 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $550.62, for a total transaction of $3,054,289.14. Following the sale, the chief executive officer now directly owns 43,608 shares in the company, valued at approximately $24,011,436.96. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Royal Bank of Canada boosted their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. HSBC upped their price target on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a report on Wednesday. Raymond James upped their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Evercore ISI upped their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Finally, Barclays cut shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Five research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $604.69.

Thermo Fisher Scientific Stock Down 1.4 %

Shares of TMO stock traded down $7.41 during mid-day trading on Thursday, hitting $539.84. 1,412,745 shares of the stock traded hands, compared to its average volume of 1,537,828. The stock has a market cap of $206.06 billion, a P/E ratio of 34.94, a P/E/G ratio of 2.33 and a beta of 0.80. The stock’s fifty day moving average is $571.57 and its two-hundred day moving average is $527.01. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating the consensus estimate of $5.64 by $0.03. The business had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company’s quarterly revenue was down 4.9% on a year-over-year basis. During the same period in the prior year, the firm posted $5.40 earnings per share. Equities analysts predict that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a $0.39 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.